Developer docs
API playgroundTry for free, no card

Search company profiles

Cyclomedica

Full company profile

uuid003lvq9

Namestring
Cyclomedica
Legal namestring
Cyclopharm Limited
Websiteurl
cyclomedica.com
Company typeenum
Public
Founded yearint
1986
Descriptiontext

Cyclomedica, the primary operating division of ASX-listed Cyclopharm Limited (ASX: CYC), is a nuclear medicine and molecular imaging company built around its proprietary Technegas® technology — a structured ultra-fine dispersion of Technetium-99m-labeled carbon nanoparticles produced by micro-furnacing dried Tc-99m in a carbon crucible at approximately 2,700°C and inhaled by patients for functional lung ventilation imaging under gamma or SPECT cameras. The Technegas Plus System generator pairs with per-patient administration sets and is compatible with 3D SPECT and hybrid CT, supported by named endorsement in EANM (2009) and Canadian Association of Nuclear Medicine (2019) guidelines as the preferred functional lung ventilation imaging agent.

The company's revenue model combines upfront capital equipment sales (Technegas Plus generators) with a high-margin, annuity-style recurring stream from per-patient consumables and administration sets, supplemented by a fast-growing third-party radiopharmaceutical distribution business in Europe and Asia-Pacific. Cyclomedica has historically sold through a global network spanning 65-66 countries, with wholly-owned subsidiaries in the US, Europe, UK, Canada, Germany, the Nordics, Benelux, and Latin America, complemented by third-party distributors across Asia, the Middle East, Africa, and Latin America. Following USFDA approval in September 2023, the company has built a direct US enterprise sales force targeting the VA, DoD, and major hospital networks, with CMS transitional pass-through status enabling national reimbursement. Primary customers are hospital nuclear medicine departments and imaging centers; secondary targets include pulmonology, thoracic surgery, and oncology use cases as the company executes its Beyond-PE strategy covering COPD, asthma, lung cancer, pulmonary hypertension, and long COVID.

Short descriptiontext

Cyclomedica is a global nuclear medicine company whose proprietary Technegas® technology delivers functional lung ventilation imaging via inhaled radioactive carbon nanoparticles, serving hospital nuclear medicine departments, VA/DoD, and research institutions across 65+ countries, with a growing US commercial footprint following 2023 FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nuclear medicine imaging, pulmonary ventilation imaging, radiopharmaceutical devices, lung diagnostic equipment, functional lung imaging
Industry4 codes
PRIMARYHLAKANAC
Pulmonary Function Testing (PFT) & Respiratory Diagnostics
SECONDARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYIMAEACAF
Medical & Healthcare Gases
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Nuclear Medicine and Pulmonary Diagnostic Imaging
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Technegas Product Sales
TypeHardware Sales
Description

Sales of Technegas generators and associated equipment to healthcare facilities. Core product sales form a significant revenue stream with recurring demand from nuclear medicine departments worldwide.

cyclomedica.com
2Per-Patient Consumables and Administration Sets
TypeSubscription Recurring
Description

Majority of revenues generated from recurring per-patient consumables including patient administration sets. This annuity-style revenue model provides predictable recurring revenue as each procedure requires consumables.

cyclomedica.com
3Third-Party Distribution
TypeTransaction Fee
Description

Distribution of third-party radiopharmaceutical products and consumables through the company's established regulatory, sales, and service network in Europe and Asia-Pacific. This business has shown exceptional growth, more than doubling revenue contribution in 2022.

cyclomedica.com
4US Market Revenue
TypeHardware Sales
Description

Following FDA approval in September 2023, the company is generating revenue from US market sales targeting pulmonary embolism diagnosis, with initial addressable market of US$180 million per annum for PE diagnosis alone.

cyclomedica.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cyclomedica develops, manufactures, and globally distributes Technegas®, a proprietary structured ultra-fine radioactive carbon (Tc-99m labeled) aerosol for lung ventilation imaging, paired with the Technegas Plus System generator device. The product is used by nuclear medicine departments to diagnose pulmonary embolism and assess other respiratory conditions including COPD, asthma, and CTEPH under SPECT/CT imaging. Revenue is generated through sales of the generator hardware and recurring per-patient consumable administration sets across 65+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 5+ million patient procedures performed globally
+5 more records
Product overview1 text field

Cyclomedica offers a focused product portfolio centered on Technegas®, a proprietary radiopharmaceutical technology for functional lung ventilation imaging. The core offering consists of Technegas® (the radioactive labeled carbon compound) paired with the Technegas Plus System (the generator/delivery hardware). The portfolio also includes variations such as Pertechnegas (a Technegas variant) and Galligas (a PET variant using Ga-68). The company has expanded its clinical applications from the primary pulmonary embolism indication into broader respiratory conditions including COPD, asthma, CTEPH, and lung cancer, under its 'Beyond PE' strategy. Cyclomedica operates primarily as a medical device and radiopharmaceutical company rather than a software platform, with operations spanning 65-67 countries through subsidiaries and distribution partners.

Product and service4 records
1Technegas®
CategoryPulmonary Ventilation Imaging Radiopharmaceutical
Description

A structured ultra-fine dispersion of radioactive labeled carbon (Technetium-99m labeled carbon inhalation aerosol) produced by micro-furnacing dried Technetium-99m in a carbon crucible at approximately 2,700°C. The gas-like substance is inhaled by patients via a breathing apparatus for lung ventilation imaging using gamma or SPECT cameras, primarily used for diagnosing pulmonary embolism and other respiratory conditions including COPD, asthma, CTEPH, and lung cancer.

2Technegas Plus System
CategoryMedical Device - Radiopharmaceutical Generator
Description

A generator system for preparing Technegas, featuring an LCD display, remote delivery switch, automatic high intensity LED, leaded safety viewing window, argon gas hose with flow restrictor, ergonomic base with four locking casters, and patient breathing apparatus for uniform delivery from Apex to Base in supine position. Used by nuclear medicine departments and imaging centers.

3Pertechnegas
CategoryPulmonary Imaging Radiopharmaceutical Variant
Description

A variation of Technegas developed in 1995 as an alternative formulation for pulmonary imaging applications.

4Galligas
CategoryPET Imaging Radiopharmaceutical
Description

A PET (Positron Emission Tomography) variation of Technegas using Ga-68 (Gallium-68) as the radioactive isotope, developed in 2000 for PET imaging of lung ventilation.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-21
Description

Research partnership with Western University's Robarts Research Institute in London, Ontario to investigate Technegas technology for detecting and quantifying mild asthma in young adults (aged 17-35). The PAXT1 clinical trial will study 40 participants to determine if Technegas can identify hidden ventilation issues even when asthma appears mild. Led by Professor Grace Parraga, world-renowned lung imaging expert. Cyclopharm contributes CAD $305,256 over 12 months. If successful, could support shift in clinical practice for asthma detection.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-03
Description

US government reimbursement approval enabling Technegas commercial rollout in United States through CMS transitional pass-through status, facilitating rapid market adoption and installation growth.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Cardinal Health operates one of the largest radiopharma distribution networks in the US. Comparable as a distributor of nuclear medicine products to hospitals, an adjacent channel role to Cyclomedica's third-party distribution business that grew 124% in a recent year.

TypeBroad incumbent
Description

Philips is a broad medical imaging incumbent with SPECT and hybrid scanner systems used alongside Technegas procedures. Comparable as the imaging modality infrastructure provider in the same clinical pathway for pulmonary embolism and COPD diagnosis.

TypeDirect peer
Description

Curium is one of the largest nuclear medicine manufacturers globally, supplying Tc-99m generators and a wide range of SPECT radiopharmaceuticals. It is the closest direct competitor in supplying diagnostic imaging agents to nuclear medicine departments where Technegas is used.

TypeBroad incumbent
Description

GE HealthCare is a global incumbent in medical imaging including SPECT/CT scanners and nuclear medicine equipment. While not a direct Technegas competitor, its installed base of nuclear medicine cameras defines the addressable market for ventilation imaging agents like Technegas.

TypeBroad incumbent
Description

Bracco is a global imaging agent manufacturer spanning CT, MRI and radiopharmaceutical contrast products. Comparable as a broad diagnostic imaging player with overlapping hospital channels where nuclear medicine and ventilation imaging are procured.

TypeEmerging player
Description

Jubilant operates a radiopharma business with nuclear medicine products and distribution across multiple geographies. Comparable as a regional/emerging nuclear medicine player competing for hospital radiopharma budgets adjacent to Technegas procedures.

TypeDirect peer
Description

Lantheus is a leading radiopharmaceutical-focused company (e.g., Definity, Xenon-133 historically) with overlapping products in lung/ventilation imaging and nuclear medicine distribution. Both companies develop and commercialise radiopharmaceutical agents consumed per-procedure in nuclear medicine departments.

TypeBroad incumbent
Description

Siemens Healthineers supplies SPECT and hybrid SPECT/CT imaging systems and broad nuclear medicine workflow solutions to hospitals. As a major scanner vendor, it shapes adoption of functional lung imaging modalities including Technegas-enabled ventilation studies.

TypeBroad incumbent
Description

Bayer's radiology business historically included radiopharmaceuticals (e.g., Xofigo legacy portfolio) and contrast media used in diagnostic imaging workflows. Comparable as a broad radiopharmaceutical and imaging agent incumbent with overlapping institutional buyers.

TypeOthers
Description

PETNET is a major PET radiopharma distributor and manufacturer in the US and Europe, part of Siemens Healthineers. Adjacent infrastructure/distribution peer that supplies radiopharmaceuticals to the same nuclear medicine departments targeted by Cyclomedica.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cyclomedica

Nuclear Medicine and Pulmonary Diagnostic Imagingcyclomedica.com

Cyclomedica is a global nuclear medicine company whose proprietary Technegas® technology delivers functional lung ventilation imaging via inhaled radioactive carbon nanoparticles, serving hospital nuclear medicine departments, VA/DoD, and research institutions across 65+ countries, with a growing US commercial footprint following 2023 FDA approval.

What Cyclomedica does

Cyclomedica, the primary operating division of ASX-listed Cyclopharm Limited (ASX: CYC), is a nuclear medicine and molecular imaging company built around its proprietary Technegas® technology — a structured ultra-fine dispersion of Technetium-99m-labeled carbon nanoparticles produced by micro-furnacing dried Tc-99m in a carbon crucible at approximately 2,700°C and inhaled by patients for functional lung ventilation imaging under gamma or SPECT cameras. The Technegas Plus System generator pairs with per-patient administration sets and is compatible with 3D SPECT and hybrid CT, supported by named endorsement in EANM (2009) and Canadian Association of Nuclear Medicine (2019) guidelines as the preferred functional lung ventilation imaging agent.

The company's revenue model combines upfront capital equipment sales (Technegas Plus generators) with a high-margin, annuity-style recurring stream from per-patient consumables and administration sets, supplemented by a fast-growing third-party radiopharmaceutical distribution business in Europe and Asia-Pacific. Cyclomedica has historically sold through a global network spanning 65-66 countries, with wholly-owned subsidiaries in the US, Europe, UK, Canada, Germany, the Nordics, Benelux, and Latin America, complemented by third-party distributors across Asia, the Middle East, Africa, and Latin America. Following USFDA approval in September 2023, the company has built a direct US enterprise sales force targeting the VA, DoD, and major hospital networks, with CMS transitional pass-through status enabling national reimbursement. Primary customers are hospital nuclear medicine departments and imaging centers; secondary targets include pulmonology, thoracic surgery, and oncology use cases as the company executes its Beyond-PE strategy covering COPD, asthma, lung cancer, pulmonary hypertension, and long COVID.

Cyclomedica firmographics

Firmographics
Name
Cyclomedica
Legal name
Cyclopharm Limited
Website
https://cyclomedica.com
Company type
Public
Founded year
1986
Operating status
Operating
Headcount range
1–10 employees
Short description
Cyclomedica is a global nuclear medicine company whose proprietary Technegas® technology delivers functional lung ventilation imaging via inhaled radioactive carbon nanoparticles, serving hospital nuclear medicine departments, VA/DoD, and research institutions across 65+ countries, with a growing US commercial footprint following 2023 FDA approval.
Ownership category
akta.pro rank

Cyclomedica industry classification

Industry
Product category
Nuclear Medicine and Pulmonary Diagnostic Imaging
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAKANAC
Pulmonary Function Testing (PFT) & Respiratory Diagnostics
SECONDARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYIMAEACAF
Medical & Healthcare Gases

Keywords

  • Nuclear medicine imaging
  • Pulmonary ventilation imaging
  • Radiopharmaceutical devices
  • Lung diagnostic equipment
  • Functional lung imaging

Where Cyclomedica is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices10 records

Markets served

Cyclomedica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Technegas Product Sales: Sales of Technegas generators and associated equipment to healthcare facilities. Core product sales form a significant revenue stream with recurring demand from nuclear medicine departments worldwide.
  2. Per-Patient Consumables and Administration Sets: Majority of revenues generated from recurring per-patient consumables including patient administration sets. This annuity-style revenue model provides predictable recurring revenue as each procedure requires consumables.
  3. Third-Party Distribution: Distribution of third-party radiopharmaceutical products and consumables through the company's established regulatory, sales, and service network in Europe and Asia-Pacific. This business has shown exceptional growth, more than doubling revenue contribution in 2022.
  4. US Market Revenue: Following FDA approval in September 2023, the company is generating revenue from US market sales targeting pulmonary embolism diagnosis, with initial addressable market of US$180 million per annum for PE diagnosis alone.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Cyclomedica product offering

Product offering

Core offering

Cyclomedica develops, manufactures, and globally distributes Technegas®, a proprietary structured ultra-fine radioactive carbon (Tc-99m labeled) aerosol for lung ventilation imaging, paired with the Technegas Plus System generator device. The product is used by nuclear medicine departments to diagnose pulmonary embolism and assess other respiratory conditions including COPD, asthma, and CTEPH under SPECT/CT imaging. Revenue is generated through sales of the generator hardware and recurring per-patient consumable administration sets across 65+ countries.

Product overview

Cyclomedica offers a focused product portfolio centered on Technegas®, a proprietary radiopharmaceutical technology for functional lung ventilation imaging. The core offering consists of Technegas® (the radioactive labeled carbon compound) paired with the Technegas Plus System (the generator/delivery hardware). The portfolio also includes variations such as Pertechnegas (a Technegas variant) and Galligas (a PET variant using Ga-68). The company has expanded its clinical applications from the primary pulmonary embolism indication into broader respiratory conditions including COPD, asthma, CTEPH, and lung cancer, under its 'Beyond PE' strategy. Cyclomedica operates primarily as a medical device and radiopharmaceutical company rather than a software platform, with operations spanning 65-67 countries through subsidiaries and distribution partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • Technegas® A structured ultra-fine dispersion of radioactive labeled carbon (Technetium-99m labeled carbon inhalation aerosol) produced by micro-furnacing dried Technetium-99m in a carbon crucible at approximately 2,700°C. The gas-like substance is inhaled by patients via a breathing apparatus for lung ventilation imaging using gamma or SPECT cameras, primarily used for diagnosing pulmonary embolism and other respiratory conditions including COPD, asthma, CTEPH, and lung cancer.
  • Technegas Plus System A generator system for preparing Technegas, featuring an LCD display, remote delivery switch, automatic high intensity LED, leaded safety viewing window, argon gas hose with flow restrictor, ergonomic base with four locking casters, and patient breathing apparatus for uniform delivery from Apex to Base in supine position. Used by nuclear medicine departments and imaging centers.
  • Pertechnegas A variation of Technegas developed in 1995 as an alternative formulation for pulmonary imaging applications.
  • Galligas A PET (Positron Emission Tomography) variation of Technegas using Ga-68 (Gallium-68) as the radioactive isotope, developed in 2000 for PET imaging of lung ventilation.

Quantifiable outcome

  • 5+ million patient procedures performed globally
  • +5 more outcomes

Companies that use Cyclomedica

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Cyclomedica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cyclomedica partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Western University (Canada)coreStrategic or Co-development Partner · 21 November 2025Research partnership with Western University's Robarts Research Institute in London, Ontario to investigate Technegas technology for detecting and quantifying mild asthma in young adults (aged 17-35). The PAXT1 clinical trial will study 40 participants to determine if Technegas can identify hidden ventilation issues even when asthma appears mild. Led by Professor Grace Parraga, world-renowned lung imaging expert. Cyclopharm contributes CAD $305,256 over 12 months. If successful, could support shift in clinical practice for asthma detection.
  • CMS (Centers for Medicare & Medicaid Services)coreStrategic or Co-development Partner · 3 September 2024US government reimbursement approval enabling Technegas commercial rollout in United States through CMS transitional pass-through status, facilitating rapid market adoption and installation growth.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Cyclomedica competitors and assessment

Company assessment

Others

  • Cardinal Health Nuclear & Precision Health Solutions: Cardinal Health operates one of the largest radiopharma distribution networks in the US. Comparable as a distributor of nuclear medicine products to hospitals, an adjacent channel role to Cyclomedica's third-party distribution business that grew 124% in a recent year.
  • PETNET Solutions (Siemens): PETNET is a major PET radiopharma distributor and manufacturer in the US and Europe, part of Siemens Healthineers. Adjacent infrastructure/distribution peer that supplies radiopharmaceuticals to the same nuclear medicine departments targeted by Cyclomedica.

Broad incumbents

  • Philips Healthcare: Philips is a broad medical imaging incumbent with SPECT and hybrid scanner systems used alongside Technegas procedures. Comparable as the imaging modality infrastructure provider in the same clinical pathway for pulmonary embolism and COPD diagnosis.
  • GE HealthCare: GE HealthCare is a global incumbent in medical imaging including SPECT/CT scanners and nuclear medicine equipment. While not a direct Technegas competitor, its installed base of nuclear medicine cameras defines the addressable market for ventilation imaging agents like Technegas.
  • Bracco Imaging: Bracco is a global imaging agent manufacturer spanning CT, MRI and radiopharmaceutical contrast products. Comparable as a broad diagnostic imaging player with overlapping hospital channels where nuclear medicine and ventilation imaging are procured.
  • Siemens Healthineers: Siemens Healthineers supplies SPECT and hybrid SPECT/CT imaging systems and broad nuclear medicine workflow solutions to hospitals. As a major scanner vendor, it shapes adoption of functional lung imaging modalities including Technegas-enabled ventilation studies.
  • Bayer Radiology: Bayer's radiology business historically included radiopharmaceuticals (e.g., Xofigo legacy portfolio) and contrast media used in diagnostic imaging workflows. Comparable as a broad radiopharmaceutical and imaging agent incumbent with overlapping institutional buyers.

Direct peers

  • Curium Pharma: Curium is one of the largest nuclear medicine manufacturers globally, supplying Tc-99m generators and a wide range of SPECT radiopharmaceuticals. It is the closest direct competitor in supplying diagnostic imaging agents to nuclear medicine departments where Technegas is used.
  • Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company (e.g., Definity, Xenon-133 historically) with overlapping products in lung/ventilation imaging and nuclear medicine distribution. Both companies develop and commercialise radiopharmaceutical agents consumed per-procedure in nuclear medicine departments.

Emerging players

  • Jubilant Pharmova (Radiopharma): Jubilant operates a radiopharma business with nuclear medicine products and distribution across multiple geographies. Comparable as a regional/emerging nuclear medicine player competing for hospital radiopharma budgets adjacent to Technegas procedures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cyclomedica social profiles

Digital presence

Cyclomedica compliance and trust

Trust signal

Compliance3 records

Cyclomedica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cyclomedica leadership team

Management profile

Number of profiles

Profiles3 records

Cyclomedica subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Cyclomedica funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cyclomedica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyclomedica

What does Cyclomedica do?

Cyclomedica develops, manufactures, and globally distributes Technegas®, a proprietary structured ultra-fine radioactive carbon (Tc-99m labeled) aerosol for lung ventilation imaging, paired with the Technegas Plus System generator device. The product is used by nuclear medicine departments to diagnose pulmonary embolism and assess other respiratory conditions including COPD, asthma, and CTEPH under SPECT/CT imaging. Revenue is generated through sales of the generator hardware and recurring per-patient consumable administration sets across 65+ countries.

Is Cyclomedica a public or private company?

Cyclomedica is a public company. It is classified as public and is currently operating.

When was Cyclomedica founded?

Cyclomedica was founded in 1986. It employs 1 to 10 people.

Where is Cyclomedica based?

Cyclomedica is headquartered in Dublin, Ireland, in the Europe region.

How does Cyclomedica make money?

Four revenue lines are on record. Technegas Product Sales are the primary driver. The others are per-Patient Consumables and Administration Sets, third-Party Distribution and US Market Revenue.

Who are Cyclomedica's main competitors?

Others on record are Cardinal Health Nuclear & Precision Health Solutions and PETNET Solutions (Siemens). Broad incumbents are Philips Healthcare, GE HealthCare, Bracco Imaging, Siemens Healthineers and Bayer Radiology. Direct peers are Curium Pharma and Lantheus Holdings. Jubilant Pharmova (Radiopharma) is listed as an emerging player.

Does Cyclomedica have an API?

No public API is recorded for Cyclomedica.

What industry is Cyclomedica in?

Cyclomedica's product category is Nuclear Medicine and Pulmonary Diagnostic Imaging. Its primary akta.pro industry code is HLAKANAC, Pulmonary Function Testing (PFT) & Respiratory Diagnostics, with a secondary code of HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales